Drug Combination Details

General Information of the Combination (ID: C73964)
Name Atractylenolide 1   NP Info  + Erlotinib   Drug Info 
Structure +
Disease
Lung cancer [ICD-11: 2C25]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Down-regulation Expression CYB5R2  Molecule Info 
Pathway MAP
Down-regulation Expression EZH2  Molecule Info 
Pathway MAP
                    In-vitro Model NCI-H1299 CVCL_0060 Lung large cell carcinoma Homo sapiens
A-549 CVCL_0023 Lung adenocarcinoma Homo sapiens
                    In-vivo Model A549 cells, carrying the luciferase reporter gene (1x107 cells), were subcutaneously injectinto the mice.
                    Experimental
                    Result(s)		 Targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer.
References
Reference 1 Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells. Cell Physiol Biochem. 2018;49(4):1615-1632.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link